Stockholders’ Equity (Details) - USD ($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
|
|
|
|
|
|
|
|
|
May 05, 2026 |
Apr. 24, 2026 |
Dec. 10, 2025 |
Oct. 21, 2025 |
Oct. 02, 2025 |
Sep. 30, 2025 |
Sep. 10, 2025 |
Jul. 17, 2025 |
Jul. 01, 2025 |
Jun. 11, 2025 |
May 06, 2025 |
Apr. 17, 2025 |
Apr. 01, 2025 |
Jan. 07, 2025 |
Nov. 15, 2024 |
Apr. 01, 2024 |
Jun. 30, 2026 |
Mar. 31, 2026 |
Dec. 31, 2025 |
Sep. 30, 2025 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Sep. 30, 2025 |
Apr. 22, 2026 |
Mar. 24, 2026 |
Feb. 09, 2026 |
Dec. 08, 2025 |
Sep. 29, 2025 |
Sep. 19, 2025 |
Jul. 31, 2025 |
Jun. 09, 2025 |
Apr. 29, 2023 |
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reverse stock split |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1-for-25
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock authorized |
|
|
|
|
|
250,000,000
|
|
|
|
|
|
|
|
|
|
|
250,000,000
|
|
|
250,000,000
|
|
|
250,000,000
|
|
250,000,000
|
|
|
|
|
|
|
|
|
|
| Bid price per share (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1
|
|
|
|
|
|
$ 1
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued |
|
4,730,457
|
|
|
|
|
5,142,858
|
|
|
|
|
|
|
|
|
|
|
|
|
442,715
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock par value (in Dollars per share) |
|
|
|
|
|
$ 0.001
|
|
|
|
|
|
|
|
|
|
|
$ 0.001
|
|
|
$ 0.001
|
|
|
$ 0.001
|
|
$ 0.001
|
|
|
|
|
|
|
|
|
|
| Preferred stock value issued (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock shares of votes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of common stock (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 107,510
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds (in Dollars) |
|
|
|
|
|
|
$ 9,000,000
|
$ 9,000,000
|
|
$ 6,001,962
|
|
|
$ 1,999,873
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds (in Dollars) |
|
|
|
|
|
|
$ 7,619,854
|
|
|
5,430,836
|
|
|
$ 1,743,757
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
|
$ 13,196,000
|
|
|
|
|
|
|
$ 222,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
7.00%
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price (in Dollars per share) |
|
$ 0.985
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
|
|
|
|
|
|
5,142,858
|
272,727
|
|
|
816,738
|
|
121,739
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of placement agent fee |
|
|
7.00%
|
|
|
|
7.00%
|
7.00%
|
|
7.00%
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent fee expenses (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,800,000
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of common stock price per share (in Dollars per share) |
|
|
|
|
|
|
|
$ 1.09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds (in Dollars) |
|
|
|
|
|
|
|
$ 7,546,988
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of additional placement agent fee |
|
|
|
|
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 818
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant reprice (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
$ 0.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair Value of Estimated Price of Warrants (in Dollars) |
|
|
|
|
|
|
|
|
|
|
$ 11,136,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant price per share (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.58
|
|
|
|
|
|
|
|
| Proceeds from Issuance or Sale of Equity (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 657,284
|
$ 3,471,866
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 626,843
|
$ 3,294,446
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reserved an additional shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,000,000
|
|
|
|
|
|
15,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Granted shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
350,000
|
|
|
|
|
|
|
|
| Aggregate intrinsic value (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 203,000
|
|
|
|
|
|
|
|
| Expire term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 years 8 months 26 days
|
|
|
|
|
|
2 years 8 months 26 days
|
|
|
|
|
|
|
|
|
|
|
|
| Stock Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Options outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
836,310
|
|
|
|
|
|
836,310
|
|
|
|
|
|
|
839,510
|
|
|
|
|
| Unrecognized total compensation (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 649,996
|
|
|
|
|
|
$ 649,996
|
|
|
|
|
|
|
|
|
|
|
|
| Term of options outstanding |
|
|
|
|
|
6 years 10 months 24 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6 years 1 month 2 days
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 29.31
|
|
|
|
|
|
$ 29.31
|
|
|
|
|
|
|
$ 30.09
|
|
|
|
|
| Aggregate intrinsic value (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
| Board of Directors Chairman [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
|
|
660,550
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of additional placement agent fee |
|
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.9
|
|
|
|
|
|
$ 0.9
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
|
|
|
|
|
$ 4,179,000
|
$ 8,197,000
|
|
$ 4,867,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,301,000
|
|
|
|
|
|
| Warrants purchase |
|
|
16,513,762
|
|
|
|
360,000
|
6,818,182
|
|
9,840,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of warrants (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 68,597
|
|
|
|
|
|
|
|
|
|
|
|
| Grant price per share (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.26
|
|
|
|
|
|
$ 1.26
|
|
|
|
|
|
|
|
|
|
|
|
| Common shares reserved |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
53,947,473
|
|
|
|
|
|
53,947,473
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3.91
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
Jan. 08, 2030
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,091,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Prefunded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price (in Dollars per share) |
|
|
|
$ 1.5099
|
|
|
|
|
|
$ 1.2199
|
|
|
$ 1.1499
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
|
|
|
|
|
|
|
|
|
4,380,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants exercised |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,274,131
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of warrants (in Dollars) |
|
|
|
|
|
|
|
|
|
$ 9,840,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement Agent Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
|
|
|
$ 1.92
|
$ 1.65
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
|
|
|
|
|
|
205,714
|
477,273
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent fee expenses (in Dollars) |
|
|
|
|
|
|
|
|
|
$ 150,958
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of additional placement agent fee |
|
|
|
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| July 2025 Citius Oncology Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
|
|
|
|
|
|
$ 905,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
|
|
|
$ 0.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
|
|
|
|
|
$ 3,468,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
|
|
|
|
|
|
5,142,858
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Oncology [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
|
|
|
|
|
$ 717,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Pharma [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
|
|
$ 4,995,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| December 2025 Citius Oncology Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding shares |
|
|
7,046,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
|
|
8,183,358
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds (in Dollars) |
|
|
$ 818
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Pharmaceuticals Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate intrinsic value (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
$ 0
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Pharmaceuticals [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
|
1,401,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| October 2025 Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
|
|
$ 3,973,510
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of gross proceeds. |
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Oncology Stock Plans [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common shares reserved |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,000,000
|
| Contractual term for vesting period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
| Unrecognized total compensation (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 15,224,629
|
|
|
|
|
|
$ 15,224,629
|
|
|
|
|
|
|
|
|
|
|
|
| Recognized over a weighted average period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 years 2 months 23 days
|
|
|
|
|
|
|
|
|
|
|
|
| Term of options outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4 years 2 months 23 days
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Oncology Stock Plans [Member] | Stock Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recognized over a weighted average period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 year 25 days
|
|
|
|
|
|
|
|
|
|
|
|
| 2014 Stock Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common shares reserved |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
34,667
|
|
|
|
|
|
34,667
|
|
|
|
|
|
|
|
|
|
|
|
| Options outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13,710
|
|
|
|
|
|
13,710
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 Stock Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common shares reserved |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
80,000
|
|
|
|
|
|
80,000
|
|
|
|
|
|
|
|
|
|
|
|
| Options outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
67,200
|
|
|
|
|
|
67,200
|
|
|
|
|
|
|
|
|
|
|
|
| 2020 Stock Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common shares reserved |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
124,400
|
|
|
|
|
|
124,400
|
|
|
|
|
|
|
|
|
|
|
|
| Options outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
66,000
|
|
|
|
|
|
66,000
|
|
|
|
|
|
|
|
|
|
|
|
| 2021 Stock Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common shares reserved |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
349,600
|
|
|
|
|
|
349,600
|
|
|
|
|
|
|
|
|
|
|
|
| Options outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
330,000
|
|
|
|
|
|
330,000
|
|
|
|
|
|
|
|
|
|
|
|
| 2023 Stock Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common shares reserved |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
481,400
|
|
|
|
|
|
481,400
|
|
|
|
|
|
|
|
|
|
|
|
| Options outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359,400
|
|
|
|
|
|
359,400
|
|
|
|
|
|
|
|
|
|
|
|
| Available for future grants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
118,000
|
|
|
|
|
|
118,000
|
|
|
|
|
|
|
|
|
|
|
|
| NoveCite Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common shares reserved |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Options outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,911,500
|
|
|
|
|
|
1,911,500
|
|
|
|
|
|
|
|
|
|
|
|
| Available for future grants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
88,500
|
|
|
|
|
|
88,500
|
|
|
|
|
|
|
|
|
|
|
|
| 2018 Omnibus Stock Incentive Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Term of options outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4 years 5 months 1 day
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.24
|
|
|
|
|
|
$ 0.24
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Oncology [Member] | Prefunded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock-based compensation expense (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,125,237
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Oncology Stock Plans [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Unrecognized total compensation (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,726,594
|
|
|
|
|
|
$ 1,726,594
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
83,036
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of common stock (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 83
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Contractual term for vesting period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Stock Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vested term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10 years
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
|
|
|
|
|
|
$ 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5.0438
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | July 2025 Citius Oncology Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
|
|
|
|
$ 1.65
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| July 2025 Citius Oncology Offering [Member] | Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.9
|
|
|
|
|
|
| Maturity date |
|
|
|
|
|
|
|
Jul. 17, 2030
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
|
|
|
|
|
|
|
|
|
$ 4,598,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| April 2026 Registered Direct Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding shares |
|
5,076,143
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds (in Dollars) |
|
$ 4,453,184
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
$ 1.2313
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
$ 184,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price (in Dollars per share) |
|
$ 0.9849
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
|
355,330
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants exercised |
|
34
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of placement agent fee |
|
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of warrants (in Dollars) |
|
$ 2,829,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent fee expenses (in Dollars) |
|
$ 85,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| April 2026 Registered Direct Offering [Member] | Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
$ 0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
|
345,686
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| May 2026 Warrant Inducement Transaction [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued |
12,777,778
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding shares |
511,111
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds (in Dollars) |
$ 9,730,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds (in Dollars) |
$ 1,770,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
$ 1.125
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maturity date |
Jun. 18, 2031
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
$ 903,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price (in Dollars per share) |
$ 7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
894,444
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of placement agent fee |
7.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent fee expenses (in Dollars) |
$ 85,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Sale of Stock, Percentage of Ownership before Transaction |
9.99%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant price per share (in Dollars per share) |
$ 0.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Proceeds from Issuance or Sale of Equity (in Dollars) |
$ 18,342,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| May 2026 Warrant Inducement Transaction [Member] | Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding shares |
|
|
|
|
|
5,142,858
|
|
|
|
|
|
|
|
|
|
|
|
|
816,738
|
5,142,858
|
|
|
|
|
5,142,858
|
|
|
|
|
|
|
6,818,182
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
$ 17,233,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price (in Dollars per share) |
$ 1.199
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
12,777,778
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Oncology Restricted Stock Awards [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant price per share (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.75
|
|
|
|
| Granted shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,600,000
|
|
|
|
| Aggregate intrinsic value (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 20,300,000
|
|
|
|
| Common Stock Issued for Services [Member] | Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 138,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Oncology [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent fee expenses (in Dollars) |
|
|
|
|
|
|
$ 125,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant price per share (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1
|
|
|
|
|
|
|
|
|
| Citius Oncology [Member] | Stock Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Options outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,100,000
|
|
|
|
|
|
18,100,000
|
|
|
|
|
|
|
18,100,000
|
|
|
|
|
| Term of options outstanding |
|
|
|
|
|
8 years 2 months 15 days
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7 years 3 months 7 days
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1.83
|
|
|
|
|
|
$ 1.83
|
|
|
|
|
|
|
$ 1.83
|
|
|
|
|
| Aggregate intrinsic value (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 5,386,000
|
|
|
|
|
| Citius Oncology [Member] | Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent fee expenses (in Dollars) |
|
|
|
|
|
|
|
$ 125,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Oncology [Member] | December 2025 Citius Oncology Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding shares |
|
|
|
|
|
|
|
|
|
|
15,697,024
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Oncology [Member] | Citius Oncology Stock Plans [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent fee expenses (in Dollars) |
|
|
$ 135,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Oncology [Member] | Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
$ 0.86
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Oncology [Member] | May 2026 Warrant Inducement Transaction [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
$ 0.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
$ 25,555,556
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Citius Oncology [Member] | May 2026 Warrant Inducement Transaction [Member] | Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
$ 0.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| December 2025 Citius Oncology Offering [Member] | Board of Directors Chairman [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of options granted to purchase shares |
|
|
1,155,963
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of options exercise price (in Dollars per share) |
|
|
$ 1.3625
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| December 2025 Citius Oncology Offering [Member] | Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
1.09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| At the Market Offering Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,185,249
|
289,910
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 839,468
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 808,640
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
400,000,000
|
|
|
|
|
|
400,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Vested term |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
36 months
|
|
|
|
|
|
|
|
|
|
|
|
| Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock authorized |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16,000,000
|
|
|
|
|
|
16,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Series A Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued |
|
|
|
|
|
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock par value (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
$ 0.001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock value issued (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 100
|
|
| Preferred stock shares of votes |
|
|
|
|
|
|
|
|
|
|
|
1,000,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Series A Preferred Stock [Member] | Mr. Mazur [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock value issued (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
$ 100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Series A Preferred Stock [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock authorized |
|
|
|
|
|
|
|
|
|
|
|
250,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Series A Preferred Stock [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock authorized |
|
|
|
|
|
|
|
|
|
|
|
16,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued |
|
|
|
|
|
|
|
|
|
540,000
|
|
|
465,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock shares issued |
|
|
|
|
83,036
|
|
|
|
20,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maturity date |
|
|
|
|
|
|
Mar. 10, 2031
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price (in Dollars per share) |
|
|
1.09
|
$ 1.51
|
|
|
$ 1.75
|
|
|
$ 1.22
|
|
|
$ 1.15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of warrants (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock-based compensation expense (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,719,674
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
|
|
|
|
$ 1.32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
|
|
|
|
|
$ 6,995,000
|
|
|
|
|
|
|
|
$ 104,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant price per share (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 0.9
|
|
|
|
|
|
$ 0.9
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Warrants [Member] | Board of Directors Chairman [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of common stock price per share (in Dollars per share) |
|
|
|
|
|
|
$ 1.09
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Prefunded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of shares issued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
252,137
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23,247,210
|
|
|
|
|
|
23,247,210
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
0.0001
|
$ 0.0001
|
|
|
|
|
|
$ 0.0001
|
|
|
0.0001
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price (in Dollars per share) |
|
|
$ 16,513,762
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
|
|
1,284,404
|
3,973,510
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants exercised |
|
|
15,229,358
|
2,513,510
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,513,510
|
|
4,380,000
|
|
|
|
|
|
|
|
|
|
| Gross proceeds (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 362,296
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 349,254
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock-based compensation expense (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,810,665
|
|
|
|
|
|
$ 11,879,167
|
$ 7,946,529
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Prefunded Warrants [Member] | Board of Directors Chairman [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of options granted to purchase shares |
|
|
1,284,404
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Placement Agent Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
|
|
|
|
|
|
|
|
|
344,400
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | July 2025 Citius Oncology Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price (in Dollars per share) |
|
|
|
|
|
|
|
$ 1.32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
|
|
|
$ 2.1875
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | December 2025 Citius Oncology Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price (in Dollars per share) |
|
|
$ 1.0899
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | October 2025 Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
|
|
|
1,460,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | October 2025 Offering [Member] | Prefunded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
$ 1.8875
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
|
|
|
278,146
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Citius Oncology Stock Plans [Member] | Prefunded Warrants [Member] | Stock Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Recognized over a weighted average period |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 year 5 months 1 day
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Citius Oncology Stock Plans [Member] | Citius Pharmaceuticals Warrants [Member] | Stock Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate intrinsic value (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4,579,195
|
|
|
|
|
|
$ 4,579,195
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Citius Oncology Stock Plans [Member] | Citius Pharmaceuticals Warrants [Member] | Board of Directors Chairman [Member] | Stock Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of options exercise price (in Dollars per share) |
|
|
$ 1.199
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Citius Oncology [Member] | Prefunded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common shares reserved |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
15,000,000
|
|
|
|
|
|
15,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Stock-based compensation expense (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,858,443
|
|
|
|
|
|
$ 5,968,921
|
6,022,287
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Citius Oncology Stock Plans [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Aggregate share of common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30,000,000
|
|
|
|
|
|
30,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Citius Pharma [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock-based compensation expense (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 594,437
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Citius Pharma [Member] | Prefunded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock-based compensation expense (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 249,874
|
|
|
|
|
|
$ 835,616
|
$ 1,924,242
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Citius Oncology Restricted Stock [Member] | Prefunded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Stock-based compensation expense (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,702,348
|
|
|
|
|
|
$ 5,074,630
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | October 2025 Offering [Member] | Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
$ 1.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | May 2026 Warrant Inducement Transaction [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding shares |
25,555,556
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Investor [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of common stock (in Dollars) |
|
|
|
|
$ 107,510
|
|
|
|
$ 26,600
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Investor [Member] | October 2025 Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Placement agent fee expenses (in Dollars) |
|
|
|
$ 85,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock [Member] | Minimum [Member] | Citius Oncology [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Grant price per share (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1
|
|
|
|
|
|
|
| Common Stock Offerings [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common stock |
|
|
|
|
|
|
|
6,818,182
|
|
|
|
|
|
743,496
|
480,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding shares |
|
|
|
|
|
|
|
6,818,182
|
|
|
|
|
|
743,496
|
33,600
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 3,000,000
|
$ 3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 2,657,167
|
$ 2,574,051
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase price (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 6.25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
|
|
|
|
|
|
$ 1.525
|
|
|
$ 1.4375
|
|
$ 7.8125
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maturity date |
|
|
|
|
|
|
|
|
|
Jun. 11, 2027
|
|
|
Apr. 01, 2030
|
Jan. 07, 2030
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Offering price (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 4.035
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase shares common stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
52,045
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds (in Dollars) |
|
|
$ 18,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Agent fee (in Dollars) |
|
|
$ 15,062,724
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock Offerings [Member] | Investor [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nov. 19, 2029
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,575,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock Offerings [Member] | Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Gross proceeds (in Dollars) |
|
|
|
6,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net proceeds (in Dollars) |
|
|
|
5,402,931
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Exercise price of warrants (in Dollars per share) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 6.25
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nov. 15, 2029
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock Offerings [Member] | Prefunded Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants purchase |
|
|
|
|
|
|
|
|
|
|
|
|
1,274,131
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock Offerings [Member] | October 2025 Offering [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants issued (in Dollars) |
|
|
|
$ 330,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| November 2024 Offering Agent [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Common Stock, Stock Options and Warrants [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
480,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|